These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 3365649)

  • 21. Increase in tumor pO2 by perfluorochemicals and carbogen.
    Hasegawa T; Rhee JG; Levitt SH; Song CW
    Int J Radiat Oncol Biol Phys; 1987 Apr; 13(4):569-74. PubMed ID: 3104250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased radiosensitivity of tumors by perfluorochemicals and carbogen.
    Song CW; Zhang WL; Pence DM; Lee I; Levitt SH
    Int J Radiat Oncol Biol Phys; 1985 Oct; 11(10):1833-6. PubMed ID: 3930442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of various oxygenation conditions on the enhancement by Fluosol-DA of melphalan antitumor activity.
    Teicher BA; Crawford JM; Holden SA; Cathcart KN
    Cancer Res; 1987 Oct; 47(19):5036-41. PubMed ID: 3113727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increase in pO2 and radiosensitivity of tumors by Fluosol-DA (20%) and carbogen.
    Song CW; Lee I; Hasegawa T; Rhee JG; Levitt SH
    Cancer Res; 1987 Jan; 47(2):442-6. PubMed ID: 3098409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
    Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Fluosol-DA/O2 on tumor-cell and bone-marrow cytotoxicity of nitrosoureas in mice bearing FSA-II fibrosarcoma.
    Teicher BA; Holden SA; Rose CM
    Int J Cancer; 1986 Aug; 38(2):285-8. PubMed ID: 3089945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reactions of tumors and normal tissues in mice to irradiation in the presence and absence of a perfluorochemical emulsion.
    Rockwell S; Mate TP; Irvin CG; Nierenburg M
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1315-8. PubMed ID: 3093416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical studies of a perfluorochemical emulsion as an adjunct to radiotherapy.
    Rockwell S; Irvin CG; Kelley M
    Int J Radiat Oncol Biol Phys; 1988 Oct; 15(4):913-20. PubMed ID: 3141320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of oxygen on the cytotoxicity and antitumor activity of etoposide.
    Teicher BA; Holden SA; Rose CM
    J Natl Cancer Inst; 1985 Dec; 75(6):1129-33. PubMed ID: 3934448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of dose and scheduling on growth delay of the Lewis lung carcinoma produced by the perfluorochemical emulsion, Fluosol-DA.
    Teicher BA; Rose CM
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1311-3. PubMed ID: 3093415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The influence of Fluosol-DA on the occurrence of lung metastases in Lewis lung carcinoma and B16 melanoma.
    Teicher BA; Jacobs JL; Kelley MJ
    Invasion Metastasis; 1988; 8(1):45-56. PubMed ID: 3343092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Fluosol-DA/O2 on the antitumor activity and pulmonary toxicity of bleomycin.
    Teicher BA; Lazo JS; Merrill WW; Filderman AE; Rose CM
    Cancer Chemother Pharmacol; 1986; 18(3):213-8. PubMed ID: 2433068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intermittent use of a perfluorochemical emulsion (Fluosol-DA 20%) and carbogen breathing with fractionated irradiation.
    Moulder JE; Fish BL
    Int J Radiat Oncol Biol Phys; 1988 Nov; 15(5):1193-6. PubMed ID: 3141322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variation in tumor response to fluosol-DA (20%).
    Sasai K; Ono K; Nishidai T; Tsutsui K; Shibamoto Y; Takahashi M; Abe M
    Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1149-52. PubMed ID: 2497093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potentiation of rat brain tumor therapy by fluosol and carbogen.
    Martin DF; Kimler BF; Evans RG; Morantz RA; Vats TS
    NCI Monogr; 1988; (6):119-22. PubMed ID: 3127732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Experimental studies on the effect of perfluorochemicals in tumor irradiation].
    Shinoda J; Iwai T; Hattori T; Kondo H; Sakai N; Yamada H
    Gan No Rinsho; 1984 Jan; 30(1):53-8. PubMed ID: 6700116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of perfluorochemical emulsions in cancer therapy.
    Teicher BA
    Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):875-82. PubMed ID: 1391527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New high O2 carrying perfluorochemical emulsions and/or carbogen: reactions of a human tumor xenograft to irradiation.
    Thomas C; Lartigau E; Malaise EP; Guichard M
    Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1157-60. PubMed ID: 2497094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new concentrated perfluorochemical emulsion and carbogen breathing as an adjuvant to treatment with antitumor alkylating agents.
    Teicher BA; Holden SA; Ara G; Ha CS; Herman TS; Northey D
    J Cancer Res Clin Oncol; 1992; 118(7):509-14. PubMed ID: 1624542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improvement in RBC flux, acidosis and oxygenation in tumour microregions by Fluosol-DA 20%.
    Lee I; Cunningham WP; Levitt SH
    Int J Radiat Biol; 1991 Oct; 60(4):695-705. PubMed ID: 1680148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.